PATIENT DETAILS	*Affix patient Addressograph if available
SURNAME:	FIRST NAME(S):
DATE OF BIRTH://///////_	MRN:



## NDMS Multiple Sclerosis Patient Eligibility Form Alemtuzumab (Lemtrada®)

## Form must be completed in full and saved securely in the patient's medical record for audit purposes only

TREATMENT	HSE APPROVED INDICATION	ICD10	Protocol	
			Code	
Alemtuzumab (Lemtrada®)	Alemtuzumab (Lemtrada <sup>®</sup> ) is indicated as a single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups:			
	Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) <b>OR</b>	G35	MS100a	
	Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.	G35	MS100b	

ELIGIBILITY				YES	NO	
Indication as per Protocol MS100a,b						
Eligibility criteria in Protocol MS100a,b have been satisfied						
EXCLUSIONS					NO	
All exclusion criteria laid out in protocol MS100a or MS100b have been considered						
PREVIOUS MEDICATION(S) FOR MULTIPLE SCLEROSIS						
Name of Medicine (in order of use; 1. =	Reason for change in treatment (please tick)					
first line etc.)	Adverse Event	Loss of Response	Othe	Other Reason		
1.						
2.						
3.						
4.						
5.						
PRESCRIBER DETAILS						
Prescriber Name						
Medical Registration Number						
ELIGIBILITY FORM COMPLETED BY						
Name						
Date						

Protocol: MS - Alemtuzumab	Published: 29/05/2017 Update: January 2025 Review: January 2027	Version Number: 6			
AIDMP Protocol Code: MS100a,b	Contributor: Prof Christopher McGuigan as Multiple Sclerosis Lead for the National Clinical Programme for Neurology	Page 1 of 1			
The information contained in this document is a statement of consensus from the National Clinical Programme for Neurology regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a>					